[Therapeutic drug monitoring of clonazepam].
Clonazepam is a 1-4 benzodiazepine mainly used to treat epilepsy and epileptiform convulsion state. Rapidly absorbed after oral administration, it is widely distributed in the organism and is extensively converted in metabolites, poorly or not active, eliminated mainly in urine (70%) and feces. Elimination half-life is long, around 40 h. In adult and child, several studies showed a concentration-effect relation. Meanwhile, a large inter-individual variability in the dose-concentration relation was observed. A 15-50 microg/L range of clonazepam blood concentrations appears to be retained as an acceptable target to control a majority of epileptic seizures. The Therapeutic Drug Monitoring (TDM) of clonazepam can be considered as possibly useful in case of association with CYP450 inducers or inhibitors, suspicion of poor observance, or toxicity signs.
Debruyne
Danièle
D
Service de Pharmacologie-Toxicologie, CHU Côte de Nacre, Caen, France. debruyne-d@chu-caen.fr
Pailliet-Loilier
Magalie
M
Lelong-Boulouard
Véronique
V
Coquerel
Antoine
A
Bentué-Ferrer
Danièle
D
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002998:Clonazepam / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans
D000927:Anticonvulsants; D002998:Clonazepam